Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Injects $2M into SynapDx for Autism Test Development

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is investing $2 million in SynapDx to further its development of an autism spectrum disorder test.

The investment, announced today by SynapDx, follows a $6 million Series A1 funding round completed in December to support the Lexington, Mass.-based firm's clinical study in support of the ASD test, which is intended to help physicians identify children with ASD earlier than they can today.

The test would be the first step in SynapDx's plans to build a broader menu of pediatric neurodevelopment tests, the company said.

"LabCorp and SynapDx have a shared vision about the future of diagnostics," SynapDx CEO Stanley Lapidus said in a statement. "The investment is validation of LabCorp's commitment to innovation and SynapDx's transformational approach to autism diagnostics."

SynapDx's blood-based test is being developed to measure RNA expression in order to differentiate children with a higher risk for ASDs from those with a lower risk. Its aim is to identify children with ASD by the age of 36 months.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.